Vasile Calin Vlad

Dr. Vasile Calin Vlad


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ACAngela Cozma
Angela Cozma
NSNicolae Dan Sporiș
Nicolae Dan Sporiș
ALAndrada-Luciana Lazar
Andrada-Luciana Lazar
ABAndrei Buruiană
Andrei Buruiană
AGAndreea Maria Ganea
Andreea Maria Ganea
OOOlga Hilda Orasan
Olga Hilda Orasan
Immune checkpoint inhibitors (ICIs) are an important advancement in the field of cancer treatment, significantly improving the survival of patients with a series of advanced malignancies, like melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and Hodgkin lymphoma. ICIs act upon T lymphocytes and antigen-presenting cells, targeting programmed cell death protein 1 (PD1), programmed cell death protein ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4), breaking the immune tolerance of the T cells against malignant cells and enhancing the body’s own immune response. A variety of cardiac-adverse effects are associated with ICI-based treatment, including pericarditis, arrhythmias, cardiomyopathy, and acute coronary syndrome, with myocarditis being the most studied due to its often-unexpected onset and severity. Overall, Myocarditis is rare but presents an immune-related adverse event (irAE) that has a high fatality rate. Considering the rising number of oncological patients treated with ICIs and the severity of their potential adverse effects, a good understanding and continuous investigation of cardiac irAEs is of the utmost importance. This systematic review aimed to revise recent publications (between 2016–2022) on ICI-induced cardiac toxicities and highlight the therapeutical approach and evolution in the selected cases.

21 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
ACAngela Cozma
Angela Cozma
ASAdela-Viviana Sitar-Taut
Adela-Viviana Sitar-Taut
OOOlga Hilda Orasan
Olga Hilda Orasan
DLDaniel Corneliu Leucuta
Daniel Corneliu Leucuta
TPTinca-Codruta Pocol
Tinca-Codruta Pocol
VBVioleta Tincuta Briciu
Violeta Tincuta Briciu
Background and Objectives: The term long COVID refers to patients with a history of confirmed COVID-19 infection, who present symptoms that last for at least 2 months and cannot be explained by another diagnosis. Objectives: The present study aims to determine the most common symptoms of the long COVID syndrome and their impact on the quality of life. Materials and Methods: A prospective observational study was conducted on patients diagnosed with mild and moderate COVID-19 (based on a positive SARS-CoV-2 molecular diagnostic or rapid antigen test and severity form definition) at the Clinical Hospital of Infectious Diseases, Cluj-Napoca, Romania. Clinical examinations with detailed questions about symptoms were performed at the time of the diagnosis of COVID-19 and the six-month follow-up. Two years after COVID-19 infection, patients were invited to complete an online quality-of-life questionnaire regarding long COVID symptoms. Results: A total of 103 patients (35.92% males) with a mean age of 41.56 ± 11.77 were included in this study. Of the total number of patients, 65.04% presented mild forms of COVID-19. Data regarding the vaccination status showed that 83.5% were vaccinated against SARS-CoV-2. The most common symptoms at diagnosis were cough (80.6%), fatigue (80.4%), odynophagia (76.7%), and headaches (67.6%), with female patients being statistically more likely to experience it (p = 0.014). Patients with moderate forms of the disease had higher levels of both systolic (p = 0.008) and diastolic (p = 0.037) blood pressure at diagnosis, but no statistical difference was observed in the 6-month follow-up. The most common symptoms at 2 years (in 29 respondent subjects) were represented by asthenia (51.7%), headache (34.5%), memory disorders (27.6%), abdominal meteorism (27.6%), and arthralgia (27.6%). In terms of cardiovascular symptoms, fluctuating blood pressure values (20.7%), palpitations (17.2%), and increased heart rate values (17.2%) were recorded. Conclusions: If at the time of diagnosis, the most frequent manifestations of the disease were respiratory, together with headache and fatigue, at re-evaluation, asthenia, decreased effort tolerance, and neuropsychiatric symptoms prevailed. Regarding the cardiovascular changes as part of the long COVID clinical picture, some patients developed prehypertension, palpitations, and tachycardia.

Verified
Journal Article
Open access
PDF file
LCLorena Ciumărnean
Lorena Ciumărnean
OSOliviu Florentiu Sarb
Oliviu Florentiu Sarb
NDNicu Catalin Draghici
Nicu Catalin Draghici
OSOctavia Sălăgean
Octavia Sălăgean
MMMircea Vasile Milaciu
Mircea Vasile Milaciu
GDGabriela Dogaru
Gabriela Dogaru
Multiple sclerosis (MS) is an immune-mediated disease characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. Brain plasticity, the brain’s ability to adapt its structure and function, plays a crucial role in mitigating MS’s impact. This paper explores the potential benefits of lifestyle changes and nutraceuticals on brain plasticity in the MS population. Lifestyle modifications, including physical activity and dietary adjustments, can enhance brain plasticity by upregulating neurotrophic factors, promoting synaptogenesis, and reducing oxidative stress. Nutraceuticals, such as vitamin D, omega-3 fatty acids, and antioxidants like alpha lipoic acid, have shown promise in supporting brain health through anti-inflammatory and neuroprotective mechanisms. Regular physical activity has been linked to increased levels of brain-derived neurotrophic factor and improved cognitive function. Dietary interventions, including caloric restriction and the intake of polyphenols, can also positively influence brain plasticity. Integrating these lifestyle changes and nutraceuticals into the management of MS can provide a complementary approach to traditional therapies, potentially improving neurological outcomes and enhancing the quality of life for the MS population.

Verified
Journal Article
Open access
PDF file
ACAngela Cozma
Angela Cozma
ASAdela-Viviana Sitar-Taut
Adela-Viviana Sitar-Taut
OOOlga Hilda Orasan
Olga Hilda Orasan
VBVioleta Tincuta Briciu
Violeta Tincuta Briciu
DLDaniel Corneliu Leucuta
Daniel Corneliu Leucuta
Lucia Maria ProcopciucLucia Maria Procopciuc
Lucia Maria Procopciuc
The COVID-19 pandemic has raised awareness of the virus’s long-term non-pulmonary consequences. This study examined the relationship between genetic polymorphisms of VEGF and cardiac dysfunction and subclinical atherosclerosis in patients recovering from COVID-19. This study included 67 patients previously diagnosed with COVID-19. VEGF-936C/T, VEGF-634G/C, and VEGF-2578C/A statuses were determined. Conventional echocardiography and arterial parameters assessments were performed at inclusion and at six months after the first assessment. For VEGF-936C/T, dominant and over-dominant models showed a significant increase in ejection fraction at six months after COVID (p = 0.044 and 0.048) and was also a predictive independent factor for the augmentation index (β = 3.07; p = 0.024). The dominant model showed a rise in RV-RA gradient (3.702 mmHg) (p = 0.028 95% CI: 0.040–7.363), with the over-dominant model indicating a greater difference (4.254 mmHg) (p = 0.025 95% CI: 0.624–7.884). The findings for VEGF-634G/C were not statistically significant, except for a difference in TAPSE during initial evaluation, using the codominant model. For VEGF-2578C/A, a difference in ventricular filling pressure (E/E’ratio) was best described under the recessive model. Our research suggests that the VEG-936C/T genotype may impact the baseline level and subsequent changes in cardiac function and subclinical atherosclerosis. These findings offer valuable insights into the complex correlation between genetic polymorphisms and cardiovascular disfunction in long COVID patients.

9 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LCLorena Ciumărnean
Lorena Ciumărnean
OSOliviu Florentiu Sarb
Oliviu Florentiu Sarb
NDNicu Catalin Draghici
Nicu Catalin Draghici
OSOctavia Salagean
Octavia Salagean
MMMircea Vasile Milaciu
Mircea Vasile Milaciu
GDGabriela Bombonica Dogaru
Gabriela Bombonica Dogaru
Multiple sclerosis (MS) is an immune-mediated disease characterized by inflammation, demyelination, and neurodegeneration within the central nervous system. Brain plasticity, the brain's ability to adapt its structure and function, plays a crucial role in mitigating MS's impact. This paper explores the potential benefits of lifestyle changes and nutraceuticals on brain plasticity in MS population. Lifestyle modifications, including physical activity and dietary adjustments, can enhance brain plasticity by upregulating neurotrophic factors, promoting synaptogenesis, and reducing oxidative stress. Nutraceuticals, such as vitamin D, omega-3 fatty acids, and antioxidants like alpha-lipoic acid, have shown promise in supporting brain health through anti-inflammatory and neuroprotective mechanisms. Regular physical activity has been linked to increased levels of brain-derived neurotrophic factor and improved cognitive function. Dietary interventions, including caloric restriction and the intake of polyphenols, can also positively influence brain plasticity. Integrating these lifestyle changes and nutraceuticals into the management of MS could provide a complementary approach to traditional therapies, potentially improving neurological outcomes and enhancing the quality of life for MS population.

18 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMircea Vasile Milaciu
Mircea Vasile Milaciu
AGAndreea-Cezara Gerdanovics
Andreea-Cezara Gerdanovics
OOOlga Hilda Orasan
Olga Hilda Orasan
ACAngela Cozma
Angela Cozma
Teodora AlexescuTeodora Alexescu
Teodora Alexescu
MPMirela-Georgiana Perné
Mirela-Georgiana Perné
Introduction: Angiosarcomas are rare malignant vascular tumors. Primary angiosarcoma of the ileum is extremely uncommon, with few cases reported in the literature. Case Report: We report the case of a 54-year-old woman who presented with abdominal pain and constipation. Endoscopic evaluation did not reveal a mass in the distal ileum; however, MRI identified a distal ileal stenosis, raising suspicion for Crohn’s disease. Surgical resection was performed, and histopathological analysis confirmed the diagnosis of primary ileal angiosarcoma. Postoperative chemotherapy was attempted but not tolerated, and the patient subsequently developed suspected peritoneal progression approximately six months after surgery. Discussion: Due to its rarity and nonspecific symptoms, ileal angiosarcoma is often diagnosed late. Imaging may suggest a vascular tumor, but definitive diagnosis requires histopathological and immunohistochemical analysis. Prognosis is generally poor, with high metastatic potential. Conclusions: This case highlights the diagnostic challenges of ileal angiosarcoma, a very rare type of tumor of the small bowel.